<p>Heparan sulfate (HS) is a polysaccharide of glycosaminoglycan type composed of alternating hexuronic acid [either glucuronic acid (GlcA) or iduronic acid (IdoA)] and glucosamine (GlcN) units that can be sulfated in various positions. HS binds to a large number of proteins and these interactions promote many biological processes, including cell adhesion and growth factor signaling. This thesis deals with the structural analysis of short heparan sulfate sequences that mediate binding to fibroblast growth factors FGF1 and FGF2, their receptor FGFR4, and the angiogenesis inhibitor endostatin.</p><p>Both FGF1 and FGF2 were shown to interact with N-sulfated hexa- and octasaccharide fragments isolated from HS. A pool of HS fragments depleted for FGF1 binding retained the ability to bind FGF2. Changes in 6-O sulfation affected binding to FGF1 but not FGF2, indicating that these proteins bind to distinct HS sequences. </p><p>All octasaccharides with high affinity for FGF1 contained an internal IdoA2S-GlcNS6S-IdoA2S trisaccharide motif as shown by exoenzyme-based sequence analysis. FGF2 bound to a mono-O-sulfated hexasaccharide with an internal IdoA2S unit, although the affinity was higher for a di-O-sulfated octasaccharide displaying an IdoA2S-GlcNS-IdoA2S trisaccharide motif. </p><p>FGFR4 was shown to bind the HS analogue heparin with a K_D value of 0.3 μM.</p><p>The interaction between FGFR4 and HS depends on both IdoA2S and GlcNS6S units. Sequence analysis suggested that the number but not the precise location of 6-O-sulfate groups determines affinity.</p><p>The HS-binding site of endostatin was identified through alanine scanning. Endostatin mutants with reduced affinity for HS were unable to counteract angiogenesis induced by FGF2. The predominant HS motif recognized by endostatin was shown to consist of two N-sulfated domains separated by N-acetylglucosamine units.</p>

<p>Angiogenesis can be defined as the formation of new blood vessels from pre-existing ones. Angiogenesis is required for development and maintenance of our vascular system and thus of fundamental importance to our existence. The endothelial cells that line the inside of the vessels de-differentiate, migrate, proliferate and re-differentiate during angiogenesis. Angiogenesis is tightly regulated, controlled by several angiogenic factors of various classes that promote angiogenesis but also by anti-angiogenic factors that counteract the effect of the pro-angiogenic factors. We have examined three factors involved in angiogenesis regulation, Vascular endotelial growth factor (VEGFR) -3, the matrix protein laminin-1 and the collagen XVIII derived fragment endostatin. </p><p>Five tyrosine phosphorylation sites in the cytoplasmic tail of VEGFR-3 were identified by phosphopeptide mapping (PPM). The data was confirmed by PPM using point-mutated receptors generated by site-directed mutagenesis.</p><p>Laminin-1 was found to promote angiogenesis in the chicken chorioallantoic membrane assay and in a synergistic fashion together with suboptimal levels of fibroblast growth factor 2 (FGF-2) in embryoid bodies. Laminin-1 also promoted endothelial tubular morphogenesis in vitro, and upregulated the expression of the endothelial differentiation marker Jagged-1. </p><p>Endostatin was shown to affect endothelial FGF-2-induced cell survival and morphogenesis. This was a result of direct binding to endothelial cells and induction of tyrosine phosphorylation of many proteins including the adaptor protein Shb. The apoptotic and morphogenic responses induced by endostatin was shown to be dependent on Shb. Further, endostatin inhibited endothelial migration and affected molecules implicated in migration. In particular, FGF-2 induced actin reorganization, and β-catenin regulation was modulated by endostatin. </p>

<p>Heparan sulfate (HS) is an unbranched and negatively charged polysaccharide of the glycosaminoglycan family, based on the repeated (GlcNAcα1-4GlcAβ1-4)disaccharide structure. The HS backbone is modified by epimerization and sulfation in various positions. HS chains are composed of <i>N</i>-sulfated (NS) domains – predominant locations for further modification steps –, the poorly modified <i>N</i>-acetylated (NA) domains and the alternating NA/NS-domains. HS is present at the cell surface and in the extra-cellular matrix and interacts at these sites with various proteins involved in numerous biological processes, such as angiogenesis. Both pro- and anti-angiogenic proteins can interact with HS and this study was focused on how HS binds to the anti-angiogenic proteins endostatin (ES) and histidine-rich glycoprotein (HRGP) and to pro-angiogenic fibroblast growth factors (FGFs).</p><p>Here we show that ES recognizes NS-domains in HS spaced by NA-disaccharides, and that binding to ES is abolish through cleavage at these NA-disaccharides. HRGP335, a peptide derived from the His/Pro-rich domain of HRGP is shown to bind to heparin and HS to the same extent as full-size HRGP, in a Zn²⁺-dependent manner. Moreover, the ability of HRGP to inhibit endothelial cell migration is located to the same region of the protein. We analyzed HS structure in respect to binding to HRGP335 and FGF-2, and show that the ability of HS to bind to those proteins depends on chain length and composition. Finally, the role of HS in FGF–HS–FGF receptor ternary complexes is evaluated using biosynthetic analogs of NS-domains. For stabilization of such complexes the overall sulfation degree of HS seems to play a more pronounced role than the exact distribution of sulfate groups.</p><p>The results presented in this thesis contribute to a greater understanding of the role of HS in angiogenesis and may provide valuable information for the development of cures against angiogenesis-related disorders.</p>

Heparan sulfate (HS) is a polysaccharide of glycosaminoglycan type composed of alternating hexuronic acid [either glucuronic acid (GlcA) or iduronic acid (IdoA)] and glucosamine (GlcN) units that can be sulfated in various positions. HS binds to a large number of proteins and these interactions promote many biological processes, including cell adhesion and growth factor signaling. This thesis deals with the structural analysis of short heparan sulfate sequences that mediate binding to fibroblast growth factors FGF1 and FGF2, their receptor FGFR4, and the angiogenesis inhibitor endostatin. Both FGF1 and FGF2 were shown to interact with N-sulfated hexa- and octasaccharide fragments isolated from HS. A pool of HS fragments depleted for FGF1 binding retained the ability to bind FGF2. Changes in 6-O sulfation affected binding to FGF1 but not FGF2, indicating that these proteins bind to distinct HS sequences. All octasaccharides with high affinity for FGF1 contained an internal IdoA2S-GlcNS6S-IdoA2S trisaccharide motif as shown by exoenzyme-based sequence analysis. FGF2 bound to a mono-O-sulfated hexasaccharide with an internal IdoA2S unit, although the affinity was higher for a di-O-sulfated octasaccharide displaying an IdoA2S-GlcNS-IdoA2S trisaccharide motif. FGFR4 was shown to bind the HS analogue heparin with a KD value of 0.3 μM. The interaction between FGFR4 and HS depends on both IdoA2S and GlcNS6S units. Sequence analysis suggested that the number but not the precise location of 6-O-sulfate groups determines affinity. The HS-binding site of endostatin was identified through alanine scanning. Endostatin mutants with reduced affinity for HS were unable to counteract angiogenesis induced by FGF2. The predominant HS motif recognized by endostatin was shown to consist of two N-sulfated domains separated by N-acetylglucosamine units.

Angiogenesis can be defined as the formation of new blood vessels from pre-existing ones. Angiogenesis is required for development and maintenance of our vascular system and thus of fundamental importance to our existence. The endothelial cells that line the inside of the vessels de-differentiate, migrate, proliferate and re-differentiate during angiogenesis. Angiogenesis is tightly regulated, controlled by several angiogenic factors of various classes that promote angiogenesis but also by anti-angiogenic factors that counteract the effect of the pro-angiogenic factors. We have examined three factors involved in angiogenesis regulation, Vascular endotelial growth factor (VEGFR) -3, the matrix protein laminin-1 and the collagen XVIII derived fragment endostatin. Five tyrosine phosphorylation sites in the cytoplasmic tail of VEGFR-3 were identified by phosphopeptide mapping (PPM). The data was confirmed by PPM using point-mutated receptors generated by site-directed mutagenesis. Laminin-1 was found to promote angiogenesis in the chicken chorioallantoic membrane assay and in a synergistic fashion together with suboptimal levels of fibroblast growth factor 2 (FGF-2) in embryoid bodies. Laminin-1 also promoted endothelial tubular morphogenesis in vitro, and upregulated the expression of the endothelial differentiation marker Jagged-1. Endostatin was shown to affect endothelial FGF-2-induced cell survival and morphogenesis. This was a result of direct binding to endothelial cells and induction of tyrosine phosphorylation of many proteins including the adaptor protein Shb. The apoptotic and morphogenic responses induced by endostatin was shown to be dependent on Shb. Further, endostatin inhibited endothelial migration and affected molecules implicated in migration. In particular, FGF-2 induced actin reorganization, and β-catenin regulation was modulated by endostatin.

Heparan sulfate (HS) is an unbranched and negatively charged polysaccharide of the glycosaminoglycan family, based on the repeated (GlcNAcα1-4GlcAβ1-4) disaccharide structure. The HS backbone is modified by epimerization and sulfation in various positions. HS chains are composed of N-sulfated (NS) domains – predominant locations for further modification steps –, the poorly modified N-acetylated (NA) domains and the alternating NA/NS-domains. HS is present at the cell surface and in the extra-cellular matrix and interacts at these sites with various proteins involved in numerous biological processes, such as angiogenesis. Both pro- and anti-angiogenic proteins can interact with HS and this study was focused on how HS binds to the anti-angiogenic proteins endostatin (ES) and histidine-rich glycoprotein (HRGP) and to pro-angiogenic fibroblast growth factors (FGFs). Here we show that ES recognizes NS-domains in HS spaced by NA-disaccharides, and that binding to ES is abolish through cleavage at these NA-disaccharides. HRGP335, a peptide derived from the His/Pro-rich domain of HRGP is shown to bind to heparin and HS to the same extent as full-size HRGP, in a Zn2+-dependent manner. Moreover, the ability of HRGP to inhibit endothelial cell migration is located to the same region of the protein. We analyzed HS structure in respect to binding to HRGP335 and FGF-2, and show that the ability of HS to bind to those proteins depends on chain length and composition. Finally, the role of HS in FGF–HS–FGF receptor ternary complexes is evaluated using biosynthetic analogs of NS-domains. For stabilization of such complexes the overall sulfation degree of HS seems to play a more pronounced role than the exact distribution of sulfate groups. The results presented in this thesis contribute to a greater understanding of the role of HS in angiogenesis and may provide valuable information for the development of cures against angiogenesis-related disorders.

Made available in DSpace on 2014-10-09T12:27:15Z (GMT). No. of bitstreams: 0 / Made available in DSpace on 2014-10-09T13:57:04Z (GMT). No. of bitstreams: 0 / Dissertacao (Mestrado) / IPEN/D / Instituto de Pesquisas Energeticas e Nucleares - IPEN-CNEN/SP

Made available in DSpace on 2014-10-09T12:27:15Z (GMT). No. of bitstreams: 0 / Made available in DSpace on 2014-10-09T13:57:04Z (GMT). No. of bitstreams: 0 / A terapia gênica tem sido empregada em estudos pré-clínicos e clínicos, com o intuito de amenizar ou curar uma doença. Vetores retrovirais são uma ferramenta de transferência gênica largamente utilizada. Vetores bicistrônicos são uma alternativa interessante para o tratamento de doenças complexas. Na construção de um vetor bicistrônico pode-se empregar várias estratégias dentre elas a utilização da sequência IRES. A endostatina, fragmento do colágeno XVIII, tem sido muito utilizada na terapia anti-angiogênica devido sua ação inibitória no crescimento de células endoteliais. A imunoterapia tem sido utilizada como tratamento coadjuvante de tumores. Dentre as citocinas utilizadas, a interleucina-2 promovendo a proliferação de linfócitos T, tem sido utilizada em diversos estudos pré-clínicos e clínicos. O objetivo deste projeto foi construir e caracterizar in vitro um vetor retroviral bicistrônico codificando endostatina e interleucina-2 utlizando a sequência IRES. A construção do vetor foi realizada em três etapas, sendo comprovada a construção final por análise de restrição e seqüenciamento. Células de empacotamento foram transfectadas com o vetor, e posteriormente realizada a transdução na célula alvo. A endostatina e a interleucina-2 foram determinadas por Dot blot, seguido de análise da expressão por RT-PCR e ensaio de atividade. O vetor construído apresentou altos níveis de titulação viral, variando de 4.20x105 a 1.53x106UFC/mL. A determinação da endostatina e da interleucina-2 variaram entre 1.08 a 2.08g/106cels.24h e 0.66 a 0.89&mu;g/106cels.24h, respectivamente. A expressão da endostatina no clone NIH3T3-pLend-IRES-IL2SN foi 2 vezes superior á apresentada pelo clone NIH3T3-pLend-IRES-IL2SN. A endostatina produzida promoveu uma inibição da proliferação de 40% das células endoteliais; e a interleucina-2 promoveu uma proliferação de 10.6% de linfócitos CD4 e 8.9% de CD8. Desta forma, a construção obtida neste trabalho representa uma excelente ferramenta para estudos da biologia celular do câncer e novas estratégias terapêuticas. / Dissertacao (Mestrado) / IPEN/D / Instituto de Pesquisas Energeticas e Nucleares - IPEN-CNEN/SP

A endostatina (ES) é uma proteína inibidora da angiogênese, com ação específica sobre células endoteliais em proliferação, utilizada para tratamento de tumores sólidos. No entanto, o elevado efeito antitumoral da ES observado em animais não é reproduzido em humanos. Com o intuito de potencializar a eficácia terapêutica da ES, produzimos duas proteínas híbridas com dois domínios funcionais. O primeiro domínio é a ES, que apresenta especificidade por células endoteliais ativadas, dirigindo estas proteínas de fusão às células endoteliais em proliferação, promovendo sua internalização e seu efeito inibitório. Como segundo domínio funcional utilizamos os domínios BH3 próapoptóticos de duas proteínas BH3-only com o objetivo de promover a liberação de citocromo C e desencadear o processo de apoptose, aumentando a ação antiangiogênica da ES. Neste trabalho, foram desenhadas duas proteínas de fusão que contêm o domínio BH3 das potentes proteínas pró apoptóticas PUMA e BIM (ES-PUMA e ES-BIM), que deveriam apresentar efeito antiangiogênico potencializado em relação à ES selvagem. A inserção dos fragmentos de DNA codificantes para os domínios BH3 de PUMA e BIM no vetor contendo o gene da ES (pET-ES) foram realizadas por mutagênese sítiodirigida. Estas proteínas de fusão recombinantes foram expressas como corpos de inclusão em E.coli, renaturadas utilizando processo que utiliza alta pressão e purificadas em resina de afinidade por heparina. O tratamento de células endoteliais com as proteínas ES-PUMA e ES-BIM não levou à queda de viabilidade em ensaio de MTS ou de apoptose avaliado por citometria de fluxo, em comparação com os resultados obtidos pelo tratamento com ES. / Endostatin (ES) is an angiogenesis inhibitor protein, with specific effect on proliferating endothelial cells, used to treat solid tumors. However, the high antitumor effect observed in animals is not reproduced in humans. In order to enhance the therapeutic efficacy of ES, we produced two hybrid proteins with two functional domains. The first domain is the ES that is specific for activated endothelial cells, directing the fusion proteins to endothelial cells in proliferation, promoting the internalization and the inhibitory effect. As a second functional domain we used the pro-apoptotic BH3 domains of two BH3-only proteins in order to promote the release of cytochrome C and trigger the apoptosis process, increasing the ES antiangiogenic action. In this work, we produced two fusion proteins containing the BH3 domain of the potent pro-apoptotic proteins BIM and PUMA (PUMA-ES and ES-BIM), which should provide enhanced antiangiogenic effect in relation to ES. The insertion of DNA fragments coding for the BH3 domain and PUMA and BIM in a vector containing ES gene (pETES) was accomplished by site-directed mutagenesis. These recombinant fusion proteins were expressed as inclusion bodies in E. coli, refolded using process at high pressure and purified on heparin affinity resin. Treatment of endothelial cells with ES-PUMA and ES-BIM did not lead to loss in viability in MTS assay or increase of apoptosis evaluated by flow cytometry, in comparison with the results obtained by treatment with ES.

Abstract Overlapping genomic clones coding for the α1 chain of mouse type XV collagen (Col15a1) were isolated. The gene was found to be 110 kb in length and to contain 40 exons. Analysis of the proximal 5'-flanking region showed properties characteristic of a housekeeping gene promoter, and functional analysis identified cis-acting elements for both positive and negative regulation of Col15a1 gene expression. The general exon-intron pattern of the mouse Col15a1 gene was found to be highly similar to that of its human homologue, and comparison of 5'-flanking sequences indicated four conserved domains. The genomic area encoding the end of the N-terminal non-collagenous domain nevertheless showed marked divergence from the human form. Due to the lack of two exons coding for the N-terminal collagenous domain and a codon divergence in one exon, the mouse β1(XV) chain contains seven collagenous domains whereas the human equivalent contains nine. In order to understand the biological role of this protein, a null mutation in the Col15a1 gene was introduced into the germ line of mice. Despite the wide tissue distribution of type XV collagen, the null mice developed and reproduced normally and were indistinguishable from their wild-type littermates. After three months of age, however, microscopic analysis revealed progressive histological changes characteristic of myopathic disorder, and treadmill exercise resulted in greater skeletal muscle injury than in the wild-type mice. Irrespective of potential anti-angiogenic properties of type XV collagen-derived endostatin, the number of vessels appeared normal. Nevertheless, ultrastructural analyses revealed markedly abnormal capillaries and endothelial cell degeneration in the heart and skeletal muscle. Perfused hearts showed a diminished inotropic response, and exercise resulted in cardiac injury, changes that mimic early or mild heart disease. Thus type XV collagen appears to function as a necessary structural component for stabilizing cells with surrounding connective tissue in skeletal muscle cells and microvessels. Mice lacking the type XV collagen homologue, type XVIII collagen, showed delayed regression of blood vessels in the vitreous body of the eye and abnormal outgrowth of the retinal vessels. This suggests that collagen XVIII plays a role in regulating vascular development in the eye. Moreover, type XVIII collagen was found to be important at the surface between the inner limiting membrane and the collagen fibrils of the vitreous body. Col18a1 deficient mice serve as an animal model for the recessively inherited Knobloch syndrome, characterized by various eye abnormalities and occipital encephalocele. The results presented in this thesis indicate diverse biological roles for the closely related collagen types XV and XVIII.